Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

$300M Series D to fund continued growth of Biofourmis' innovative virtual care solutions Dr. Omar Ishrak Appointed Biofourmis Chairman BOSTON , April 26, 2022  /PRNewswire/ -- Biofourmis, a global leader in virtual care and digital medicine, today announced it has surpassed unicorn status with a $300 million Series D investment led by leading global growth equity firm General Atlantic. CVS Health (NYSE: CVS) and existing investors also participated in the round, which will help fuel the company's next phase of growth.

Biofourmis Receives Significant Growth Investment from General Atlantic to Propel Company to Unicorn Status

Texas Instruments

Companies with pricing power are a great pick for the current inflationary environment, and the way to identify such companies is to look for gross profit growth, says Degus Wright. Wright picks companies with growing gross profit A name that fits the description, as per the founder of Decatur Capital Management, is CVS Health Corp […] The post Pro: these companies with growing gross profit look attractive appeared first on Invezz.

Pro: these companies with growing gross profit look attractive

Amazon

Costco

These stocks should perform strongly should another crisis grip the global community as it did during the Covid-19 pandemic. The post 3 Stocks to Buy if Calamity Hits the Market appeared first on InvestorPlace.

3 Stocks to Buy if Calamity Hits the Market

Rite Aid

Walgreens

They're not as great as the arguments in favor might make it seem.

Why These Pharmacy Stocks Aren't a Good Option for Retirement Savings

The famous "Big Short" investor, Michael Burry, recently sold out of CVS Health Corp. ( CVS , Financial). Burry profited immensely from holding the stock during its fantastic bull run in 2021.

Why Michael Burry's CVS Sale Doesn't Make Sense

Newmont Mining

Investors are seemingly dissatisfied with this prolonged period of weak stock market returns. The market's equity risk premium, which is the return investors demand from their stock investments, has declined to its lowest level since 2018.

Investors Are Looking for Risk-Off, High-Quality Stocks

Microsoft

Target

We've put together the following list of 3 no-brainer stocks to buy with $1000 below. Let's take a deeper look at why these are great picks to consider at this time.

3 No-Brainer Stocks to Buy with $1000

Kroger

Baby formula is in high demand, and stores including Target, Kroger, Walgreens, and CVS are limiting what consumers can purchase, the WSJ reported.

Target, Kroger, Walgreens, and CVS are limiting purchases of baby formula as frantic parents face shortages

Over the past 3 years, CVS Health stock has seen a fine runup, outpacing the S&P500. After a double, shares were starting to appear overvalued.

CVS Health: Investors May Get Another Bite At The Apple

WOONSOCKET, R.I. , April 4, 2022 /PRNewswire/ -- CVS Health (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, May 4, 2022, at 8:00 a.m.

CVS Health to Hold First Quarter 2022 Earnings Conference Call

Investors are optimistic about CVS Health (CVS) owing to continued progress in its consumer-centric digital solutions.

Here's Why You Should Retain CVS Health (CVS) Stock For Now

This innovative play is definitely worth watching in the future.

CVS Is Pioneering Metaverse Health as Its Stock Keeps Climbing

Estee Lauder

Honda

HSBC Holdings

More big brands are finding their way to the metaverse. Is it time you do the same?

5 Companies That Are Proving That Metaverse Real Estate Is Red-Hot

WOONSOCKET, R.I. , April 1, 2022 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced the release of its annual Environmental, Social and Governance (ESG) report – Healthy 2030 – detailing how the company is helping create a healthier and more sustainable world.

CVS Health Environmental, Social and Governance Report Details 2021 Progress

Teva Pharmaceutical

Florida has reached more than $878 million in settlements with CVS Health Corp (NYSE: CVS) and three drug companies to resolve claims and avert a trial next month over their roles in fueling an opioid epidemic. CVS will shell out $484 million, Teva Pharmaceutical Industries Ltd.

CVS Health, Teva Settle Florida State's Opioid-Related Claims: Report

CVS and pharmaceutical companies will pay Florida a combined $860 million as part of the settlement of an opioid epidemic case, state officials said Wednesday.

CVS, drug makers settle Florida opioid lawsuit for $860M

Allergan

Endo International

Florida has reached more than $878 million of settlements with CVS Health Corp and three drug companies to resolve claims over their roles in fueling an opioid epidemic in the third most populous U.S. state.

Florida reaches $878 million opioid settlements with CVS, Teva, others

CVS Health Corp said on Wednesday it had entered into an agreement with the state of Florida to resolve claims related toprescriptions for opioid medications for $484 million to be paid over a period of 18 years.

CVS Health reaches $484 million opioid settlement with Florida

CVS Health Corp. CVS, -3.11% announced Wednesday that it has settled opioid claims in Florida based on prescriptions filled in pharmacy locations in that state. Some of the claims date back more than 10 years.

CVS settles Florida opioid claims for $484 million

WOONSOCKET, R.I. , March 30, 2022 /PRNewswire/ -- CVS Health (NYSE: CVS) announced today that it has entered into an agreement with the State of Florida to resolve claims dating back more than a decade related to prescriptions for opioid medications that were filled at Florida CVS Pharmacy locations.

CVS Health Reaches Opioid Settlement Agreement with State of Florida

In the news release, CVS Health and Fresno Housing Collaborate to Address Affordable Housing Crisis and Provide Healthy Homes in Fresno County, issued 29-Mar-2022 by CVS Health over PR Newswire, we are advised by the company that the release has been revised. The complete, corrected release follows: CVS Health and Fresno Housing Collaborate to Address Affordable Housing Crisis and Provide Healthy Homes in Fresno County WOONSOCKET, R.I.

/C O R R E C T I O N -- CVS Health/

CVS's earnings could be dented by opioid litigation as well as changes affecting its pharmacy segment, Deutsche Bank says.

Deutsche Steps to the Sidelines on CVS Health

AmerisourceBergen

Moderna

These three fundamentally sound companies will protect both your vitals and your financial livelihood for years to come.

3 Healthcare Stocks With Healthy Fundamentals

Which pharmacy retailer should you put in your portfoliio?

Better Buy: Walgreens vs. CVS Health

Huntsman

Newell Brands

Webster Financial

It is hard to believe, but the first quarter will end in a week and many investors will be reviewing their portfolios and making changes for the second quarter and the rest of 2022.

News for CVS Health Stock (CVS)